Richard young 2023

Richard Young

Managing Director and Principal Toxicologist

UKRT/ERT

Richard Young,
Managing Director and Principal Toxicologist

Richard has over 20 years’ experience in desk-based toxicology at bibra. In 2018, Richard became the Managing Director of bibra. 

Richard has worked for clients from the food and beverage, food contact materials, consumer goods, agrochemical, biocidal, industrial chemical, pharmaceutical, electronic cigarette and cannabinoid sectors. For the past 15 years, he has been heavily involved in assisting companies comply with their REACH registration obligations, including supporting registrants respond to ECHA Evaluation decisions. 

Richard has played a key role in assisting e-cigarette and e-liquid manufacturers and importers with the toxicological assessments of their products, notably with their EU TPD and US FDA PMTA compliance obligations. Most recently he has been involved in the toxicological assessment of cannabinoids (notably CBD and THC) for a number of clients from a range of sectors (e.g. food, consumer products and pharmaceuticals). 

Qualifications & Experience 

Richard has an MSc in Applied Toxicology and is a RSB/BTS and European Registered Toxicologist (ERT)

His skills include expert analysis of human health data. This can involve the pragmatic application of risk assessment methodology to mammalian toxicity data sets in order to derive robust conclusions on toxicological acceptability and health risks to exposed populations. In 2018, Richard became the Managing Director of bibra. 

Areas of Expertise 

Hobbies & Interests 

In his spare time Richard can be found playing padel tennis and 5-a-side football (when his knees can cope), and running around and entertaining his two children.

Richard's case studies and blog posts

Health risk assessments relating to the excipient components of the Voke® formulation

Case study

A novel nicotine replacement device was designed to deliver a pressurised nicotine formulation via a breath operated valve in a cigarette sized medical device. Kind Consumer received a Marketing Authorisation for its lead product, Voke®, in September 2014.

FDA memoranda: genotoxicity and carcinogenicity assessments of ENDS

Blog articles

As discussed in a previous blog post, the U.S. Food and Drug Administration (FDA) Center for Tobacco Products (CTP) has issued several “scientific policy memoranda” that provide some great insights into the Agency’s evaluation process. In June 2024, the FDA made two new memos available that relate to the genotoxicity and carcinogenicity assessment of chemical constituents of Electronic Nicotine Delivery Systems (ENDS).

Evaluating the health risks posed by extractables and leachables from an ENDS device

Case study

In order to market their latest product in the United States, the client was intending to submit a Premarket Tobacco Product Application (PMTA) for a pod-based ENDS device.

Want to read more case studies and blog posts that Richard has been involved in? Click below to read more.

Contact us